Paradoxial Safety Signals from Biologics
|
|
- Clinton Griffin
- 5 years ago
- Views:
Transcription
1 Paradoxial Safety Signals from Biologics Christopher Ritchlin, MD, MPH Professor of Medicine Director, Translational Immunology Research Center University of Rochester Medical Center Rochester, NY Disclosures Consultant Amgen Abbot Janssen UCB Pfizer Research Amgen Abbot Janssen UCB
2 Overview Cutaneous and autoimmune reactions to TNFi Pathogenesis Therapeutic approach Cutaneous reactions
3 Cutaneous lesions reported with TNFi More common Psoriasiform Palmopustular Vulgaris Scalp psorasis Intersitial granulomatous dermatitis Acute generalized exanthemaous pustulosis (AGEP) Lupus-like lesions Scattered report Sweet s Syndrome Vasculitis Guttate psoriasis Psoriasiform lesions: phenotype 114 Case Reports Underlying disorder: RA, SpA, IBD, Behcets dx Pustular 52%, Plaque 50%, guttate 15% Observed with all TNFi No causative infection, new drug introduction, stress or recent trauma identified Collamer et al. Arthritis Care Res,2008;59(7):996
4 Potential etiologies of TNFi induced psoriasis Underlying disease PsA and not RA or AS Systemic infection-chlamydia, steptococcus Reactive arthritis Drug-induced lesions Lupus Acute Granulomatous Exanthematous Pustolosis Intersititial granulomatous Acute generalized exanthematous pustulosis (AGEP) Halevy S. Current Opinion in Allergy and Clinical Immunology 2009, 9:
5 Interstitial granulomatous dermatitis Observed in SLE, RA, vasculitis and LP disorders Variable appearance: plaques, cords on trunk or extensor surfaces Observed after exposure to TNFi Deng A. Archives Derm 2006;142:198 Palmopustular psoriasis Most common in female smokers Not associated with Cw6 alleles Often resistant to therapy
6 Guttate psoriasis Tear drop lesions Associated with B23, B17 and Cw6 2 weeks after strep infection Plaque psoriasis Associated with Cw6 alleles Early and late onset Most common phenotype in the population Many psoriasiform lesions can mimic psoriasis vulgaris
7 Lupus-like Reactions to TNFi Incidence of Lupus-like reactions to TNFi: a French national survey, Arthritis Research and Therapy, cases of DIL in 866 pts in French Biologics Registry -(10 with skin disease, 12 with systemic disease) -Mean onset of symptoms occurred at 9 months in the Infliximab group and 4 months in the Etanercept group -8 patients required steroids (IV/oral/topical) -Median time for symptoms to resolve was 8 weeks (except for one) -Incidence of occurrence was 0.19% with Infliximab and 0.18% with Etanercept De Bandt M. Arthritis, Research and Therapy, 2005
8 Features of patients with ATIL Summary of data from 4 studies BSBR n=41 Costa et al (USA) n=33 Ramos Casal et al (Spain) n=71 De Bandt et al (France) n-12 Manifestation % N=158 Positive ANA 72 Immunologic Abn (anti-dsdna Ab) 65 Discoid rash 61 Hematologic Abn (cytopenias) 27 Arthritis 30 Serositis 9 Photosensitivity 5 Renal 5 Williams E. Rheumatology 2009;48:716 Autoantibody Profiles in ATIL Williams E. Rheumatology 2009;48:716
9 Pathogenesis Four arms of immune homeostasis and disease Banchereau J et al. Immunity 2004;20:539
10 Pathophysiology of Psoriasis Clark RA, Kupper TS. J Clin Inv 2006(8):2084 Proposed mechanisms of ATIL Shift to an IFN signature and Th2 profile-il-10 TNF induced necrosis of cells that release nuclosomes TNFi may interfere with apoptosis of cells and clearance of nuclear debris Decline in TREGs Sarzi-Puttini P Autoimmunity. 2005;38:507 D Auria F. J int Med. 2004;255:409 Schur, P. et al Drug-Induced Lupus, Up-to-date, 2012
11 IFN inducible proteins observed in TNFi associated psoriasis TNFi Vulgaris Epidermal myxovirus resistance Protein (MxA) De Gannes GC Arch Derm 2007;143(2):223 Effect of IL-12/23i and TNFi on psoriasiform lesions CD4+CD45RB(high)CD25- (naive CD4) T cells Ma, HL. Arthritis Rheum 2010;62(2):430
12 IL-17, 21, 22 mrna increase after TNFi Ma, HL. Arthritis Rheum 2010;62(2):430 TNF blockade associated with a decline in TREG cells Ma, HL Arthritis Rheum 2010;62(2):430
13 Rx of SS pts with ETN induced IFN signature and BAFF DBRCT of of 20 SS pts treated with ETN for 12 weeks Mavragani CP. Arthritis Rheum 2007;56(12):3995 Treatment
14 Collamer A. et al Arth Care Res 2008;59(7):996 Stop the TNFi Treatment of ATIL in most cases, the manifestations will clear in 4 to 8 weeks For patients who persist with features of SLE, corticosteroids or immunosuppressants may be required.
15 Overview Cutaneous and autoimmune reactions to TNFi Pathogenesis Therapeutic approach
Ask the Expert: Photosensitivity in Cutaneous Lupus
Ask the Expert: Photosensitivity in Cutaneous Lupus Victoria P. Werth, MD Department of Dermatology & Medicine University of Pennsylvania ; Philadelphia VA Hospital Overview Definition Impact of photosensitivity
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationUPDATES ON PEDIATRIC SLE
UPDATES ON PEDIATRIC SLE BY ANGELA MIGOWA, PEDIATRIC RHEUMATOLOGIST/SENIOR INSTRUCTOR AKUHN MBCHB-UON, MMED-AKUHN,PEDIATRIC RHEUMATOLOGY- MCGILL UNIVERSITY HEALTH CENTRE ROSA PARKS OBJECTIVES RECOGNIZE
More informationHigh Impact Rheumatology
High Impact Rheumatology Systemic Lupus Erythematosus Bernard Rubin, DO MPH Case 1: History A 45-year-old woman presents with severe dyspnea and cough. She was in excellent health until 4 weeks ago when
More informationRheumatology 101 A Pediatrician s Guide
Rheumatology 101 A Pediatrician s Guide Pediatric Staff and Alumni Day 2016 Dawn M. Wahezi, Yonit Sterba, Tamar Rubinstein Disclosures None Pick a Group Group 1 A child with a limp Group 2 ANA To test
More informationEnvironmental factors including drugs. Jyoti Ranjan Parida
Environmental factors including drugs Jyoti Ranjan Parida Scheme of presentation Pathogenesis of autoimmune disease Evidence for environmental influence Environmental factors Proposed -Role of Sunlight
More informationImmune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy
Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy Philip Mease MD Director, Rheumatology Clinical Research, Swedish- Providence St. Joseph Health Clinical Professor, University of Washington
More informationNew Therapeutic Perspectives in Sjögren's Syndrome
New Therapeutic Perspectives in Sjögren's Syndrome Claudio Vitali Chairman of the EULAR Task Force for Disease Activity Criteria in Sjögren s Syndrome. Member of the Steering Committee for the ACR- EULAR
More information6 ADRs, 2 LOE. 2 ADRs, 4 LOE. Ineffectiveness 24 ADRs 7, 1 pt for convenience. 48% had antibodies against Infliximab at baseline
Summary of Published Switch data Table 1. Information Patients Switch from (n) Reason for switch Switch to: (n) Results Numbers Presse Med. 2002 (1) 14 Infliximab (8) (6) 6 ADRs, 2 LOE 2 ADRs, 4 LOE (8)
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationCentral Nervous System (CNS) and Lupus: Learn from the Experts. Betty Diamond, M.D. Feinstein Institute for Medical Research
Central Nervous System (CNS) and Lupus: Learn from the Experts Betty Diamond, M.D. Feinstein Institute for Medical Research Stages in SLE Pathogenesis Crow MK, Arth Res & Tx. 2009 ACR Criteria for the
More informationLUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS LUPUS 101 SLE SUBSETS AUTOIMMUNE DISEASE 11/4/2013 HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS
LUPUS 101 LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS SLE SUBSETS SUBACUTE CUTANEOUS LUPUS DRUG INDUCED LUPUS NEONATAL LUPUS LATE ONSET LUPUS ANTI-PHOSPHOLIPID
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More information12 th Annual Lupus Education Day Agenda
12 th Annual Lupus Education Day Agenda 8:30 9:00 am Sign-in / Refreshments 9:00 9:05 am Introduction / Logistics 9:05 9:30 am Dr. Jennifer Anolik: What s New in the World of Lupus 9:30 10:00 am Dr. Christopher
More informationSkin Deep: Cutaneous Lupus. Dr Sarah Sasson Immunology Registrar, Liverpool Hospital 2016
Skin Deep: Cutaneous Lupus Dr Sarah Sasson Immunology Registrar, Liverpool Hospital 2016 Introduction: Cutaneous lupus erythematosus LE is an autoimmune disease with a range of clinical manifestations
More informationSystemic Medications for the Dermatology Toolbox: Azathioprine
Systemic Medications for the Dermatology Toolbox: Azathioprine Wynnis Tom, M.D. Associate Clinical Professor University of California, San Diego and Rady Children s Hospital Faculty Disclosure Information
More information10/25/2018. Autoimmunity and how to treat it. Disclosure. Why do we get autoimmunity? James Verbsky MD/PhD Pediatric Rheumatology/Immunology
Autoimmunity and how to treat it James Verbsky MD/PhD Pediatric Rheumatology/Immunology Disclosure None I will mention drug names and some brand names but I have no financial interest or any other ties
More informationAutoimmune Disease. Autoimmunity. Epidemiology. ACR Criteria for Diagnosis. Signs and Symptoms. Autoreactivity: Reactivity to self antigens:
Autoimmunity Reactivity to self antigens: Autoreactivity: Autoimmune Disease T cells B cells Leading to tissue damage or dysfunction Occurring in the absence of ongoing infection Epidemiology SLE Pathogenesis
More informationAutoimmunity. Autoimmune Disease
Autoimmunity Reactivity to self antigens: T cells B cells Autoimmune Disease Autoreactivity: Leading to tissue damage or dysfunction Occurring in the absence of ongoing infection 1 SLE Pathogenesis Immune
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationClassic DMARD s, biologic drugs and cancer risk
Classic DMARD s, biologic drugs and cancer risk Prof. Dr. António M. F. Araújo Head of the Service of Medical Oncology Centro Hospitalar do Porto Instituto de Ciências Biomédicas de Abel Salazar Disclosure
More informationGenetics and the Path Towards Targeted Therapies in Systemic Lupus
Genetics and the Path Towards Targeted Therapies in Systemic Lupus Emily Baechler Gillespie, Ph.D. University of Minnesota Department of Medicine Division of Rheumatic and Autoimmune Diseases Disclosures
More informationRheumatologic Manifestations of Gastrointestinal Diseases
Rheumatologic Manifestations of Gastrointestinal Diseases NATASHA DEHGHAN, MD, FRCPC CLINICAL ASSISTANT PROFESSOR VASCULITIS CLINIC, MARY PACK ARTHRITIS CENTRE Objectives To discuss a few common rheumatologic
More informationTHE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ
THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ Disclosures: On National Advisory Boards of: (1) Pfizer Pharmaceuticals (2) MSD (3) Roche Pharmaceuticals (4) Abbott International: AfME Rheumatology
More informationThe Role of Plasmacytoid Dendritic Cells in Psoriasis
6 ème Journée du Groupe de Recherche sur le Psoriasis Paris, 9 novembre 2012 The Role of Plasmacytoid Dendritic Cells in Psoriasis Dr Curdin Conrad, PD & MER Department of Dermatology Psoriasis: Clinical
More informationObjectives. Joint Pain. Case 1. Rheumatology for the Primary MD (Not just your grandmother s disease) 12/4/2010
Objectives Rheumatology for the Primary MD (Not just your grandmother s disease) Identify when it is appropriate to refer for rheumatologic evaluation Autoimmune/ Inflammatory v. noninflammatory disease
More informationPSORIASIS PSORIASIS. Anatomic sites FACTS ABOUT PROSIASIS PSORIASIS 11/16/2017 STIGMATA OF PSORIASIS
PSORIASIS Dr. Sami Alsuwaidan President, Saudi Society of Dermatology & Dermatologic Surgery Associate Professor and Consultant Department of Dermatology, College of Medicine King Saud University PSORIASIS
More informationTuberculosis and Biologic Therapies: Risk and Prevention
Tuberculosis and Biologic Therapies: Risk and Prevention Kevin L. Winthrop, MD, MPH Associate Professor, Divisions of Infectious Diseases, Public Health and Preventive Medicine Oregon Health & Science
More informationOriginal Article. Abstract
Original Article Diagnostic accuracy of antinuclear antibodies and anti-double stranded DNA antibodies in patients of systemic lupus erythematosus presenting with dermatological features Attiya Tareen*,
More information.,Dr Ali Alkazzaz Babylon collage of medicine 2016
.,Dr Ali Alkazzaz Babylon collage of medicine 2016 Lupus history Lupus is the Latin word for wolf 1 st used medically in the 10 th century Described clinically in the 19 th century Butterfly rash in 1845
More informationCPC. Chutika Srisuttiyakorn, M.D. Kobkul Aunhachoke, M.D. Phramongkutklao Hospital Bangkok, Thailand
CPC Chutika Srisuttiyakorn, M.D. Kobkul Aunhachoke, M.D. Phramongkutklao Hospital Bangkok, Thailand A 53 year-old woman with fever, facial swelling and rashes on face, trunk and upper extremities for 3
More informationUndifferentiated Connective Tissue Disease and Overlap Syndromes. Mark S. Box, MD
Undifferentiated Connective Tissue Disease and Overlap Syndromes Mark S. Box, MD Overlap Syndromes As many as 25% of patients with rheumatic diseases with systemic symptoms cannot be definitely diagnosed
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationRheumatologic Lab Tests
Rheumatologic Lab Tests What the Practitioner Needs to Know Mary Nakamura M.D. 2008 Rheumatologic Lab Tests Are rarely diagnostic of any specific disease If you do not have in mind a rheumatologic disease
More informationBachelor of Chinese Medicine ( ) AUTOIMMUNE DISEASES
Bachelor of Chinese Medicine (2002 2003) BCM II Dr. EYT Chan February 6, 2003 9:30 am 1:00 pm Rm 134 UPB AUTOIMMUNE DISEASES 1. Introduction Diseases may be the consequence of an aberrant immune response,
More informationHospital-based Dermatopathology. Janis M. Taube, MD Director of Dermatopathology Johns Hopkins University SOM
Hospital-based Dermatopathology Janis M. Taube, MD Director of Dermatopathology Johns Hopkins University SOM Overview Drug-eruptions Erythroderma Manifestations of renal disease Blistering disorders Vasculitis/Vasculopathy
More informationClinical Significance of Autoantibodies Induced by Infliximab Treatment: Two-Year Follow-up after Infliximab Discontinuation
2011;19(3):156-160 SHORT SCIENTIFIC COMMUNICATION Clinical Significance of Autoantibodies Induced by Infliximab Treatment: Two-Year Follow-up after Infliximab Discontinuation Srđan Novak 1, Branimir Anić
More informationSystemic Lupus Erythematosus among Jordanians: A Single Rheumatology Unit Experience
Systemic Lupus Erythematosus among Jordanians: A Single Rheumatology Unit Experience Ala M. AlHeresh MD* ABSTRACT Objectives: To study the characteristics of Systemic Lupus Erythematosus in Jordan and
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abatacept for DLE, 493 for SLE, 497 Ablative therapies, localized, for cutaneous T-cell lymphoma, 502 506. See also Cutaneous T-cell lymphoma,
More information5 TH ANNUAL PERSPECTIVES IN RHEUMATIC DISEASES
EARLY BIRD DISCOUNT AVAILABLE REGISTER NOW AT WWW.GLOBALACADEMYCME.COM/RHEUMATOLOGY Rheumatology News, Internal Medicine News & Family Practice News PRESENT A CONTINUING MEDICAL EDUCATION CONFERENCE 5
More informationLiving with Lupus: An Insider s Perspective
Living with Lupus: An Insider s Perspective Pamela Thorpe, MD, FACP Lupus Foundation of America, Inc. Philadelphia Tri-State Chapter Volunteer May 2014 My Own Story Is it Lupus Yet? The What What is this?
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationCutaneous side effects of antietumor necrosis factor biologic therapy: A clinical review
REVIEW Cutaneous side effects of antietumor necrosis factor biologic therapy: A clinical review Aikaterini-Evaggelia Moustou, MD, a Athina Matekovits, MD, a Clio Dessinioti, MD, a Christina Antoniou, MD,
More informationSystemic Lupus Erythematosus
Systemic Lupus Erythematosus Marc C. Hochberg, MD, MPH Professor of Medicine and Head, Division of Rheumatology University of Maryland School of Medicine CASE: HISTORY A 26-year-old woman is seen for migratory
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationSupplementary material
Supplementary material Table S1: Dubois Guidelines for Diagnosis of DrugInduced Lupus 1. Continuous treatment with a known lupusinducing drug for 1month and usually much longer 2. Presenting symptoms:
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1017-7 Program Prior Authorization/Notification Medication Cimzia (certolizumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,
More informationChronic Granulomatous Disease Managing GI Issues
Chronic Granulomatous Disease Managing GI Issues N I C H O L A S H A R T O G, M D D i r e c t o r o f P e d i a t r i c / A d u l t P r i m a r y I m m u n o d e f i c i e n c y C l i n i c A s s i s t
More informationMedical Dermatology Society
A Mashup of Instructive Cases Presenting With Subacute Cutaneous LE (SCLE) Skin Lesions Medical Dermatology Society Denver, Colorado March 20, 2014 Rick Sontheimer, M.D. Professor of Dermatology University
More informationPeter H. Schur Elena M. Massarotti. Editors. Lupus Erythematosus. Clinical Evaluation and Treatment
Lupus Erythematosus Peter H. Schur Elena M. Massarotti Editors Lupus Erythematosus Clinical Evaluation and Treatment Editors Peter H. Schur Division of Rheumatology, Immunology, Allergy Brigham and Women
More informationPsoriasis management. A/Prof Amanda Oakley Dermatologist, Waikato
Psoriasis management A/Prof Amanda Oakley Dermatologist, Waikato AbbVie Breakfast Session, 14 June 2014 Disclosure This breakfast session is sponsored by Abbvie Autoimmune skin disorders Psoriasis Eczema
More informationRisk of Pneumocystosis among Patients Receiving Immunosuppressive Therapies: a population based analysis in the United States
Risk of Pneumocystosis among Patients Receiving Immunosuppressive Therapies: a population based analysis in the United States Sergey Rekhtman MD, PharmD, MPH Amit Garg, MD Department of Dermatology Zucker
More informationSupplementary Tables. Psoriasis a
Supplementary Tables Supplementary Table S1 Age-sex distribution of patients with psoriasis and PPP subdivided by the department specified in a claim with a diagnosis code of psoriasis and PPP in Japanese
More informationDr. Venkateswari. R. Dr. Janani Sankar s unit Kanchi Kamakoti CHILDS Trust Hospital
Dr. Venkateswari. R. Dr. Janani Sankar s unit Kanchi Kamakoti CHILDS Trust Hospital Acknowledgements: KKCTH Dr. Ramkumar Consultant Dermatologist Dr. Ramprakash Consultant Ophthalmologist Dr. Prasad Manne
More informationApplication of genetic signatures to clinical care of lupus
Application of genetic signatures to clinical care of lupus Dr Durga Prasanna Misra MD, MRCP(UK), DM Assistant Professor Department of Clinical Immunology, JIPMER, Puducherry. LAYOUT Genetics of lupus
More informationManaging Penicillin Allergy
Managing Penicillin Allergy Brian T. Kelly, MD MA April 12, 2019 Objectives Review penicillin allergy prevalence, morbidity, and management Describe the penicillin testing and oral challenge process Provide
More informationPsoriasiform Dermatitis in Children: Calling in the Troops
Psoriasiform Dermatitis in Children: Calling in the Troops Markus Boos, MD PhD Attending Physician, Dermatology Seattle Children s Hospital Assistant Professor of Pediatrics, University of Washington School
More informationInsights into the DX of Pediatric SLE
Insights into the DX of Pediatric SLE Dr. John H. Yost Pediatric Rheumatology Children s Hospital at Dartmouth Assistant Professor of Medicine Geisel School of Medicine at Dartmouth john.h.yost@hitchcock.org
More informationA heterogeneous collection of diseases characterised by hypogammaglobulinemia.
1 Common variable immunodeficiency () A heterogeneous collection of diseases characterised by hypogammaglobulinemia. Although is the most common primary immune deficiency (PID) symptomatic in adults, it
More informationPredicting the Response to Phototherapy for Psoriasis Patients
A*STAR-NHG-NTU Skin Research Grant Joint Workshop 17 October 2015 Predicting the Response to Phototherapy for Psoriasis Patients Is it possible? Dr Eugene Tan Consultant Dermatologist National Skin Centre
More informationLupus The Clinical Perspective
Lupus The Clinical Perspective Anca D. Askanase, M.D., M.P.H. Associate Professor of Medicine Director Lupus Center Columbia University Medical Center New York-Presbyterian Hospital Systemic Lupus Erythematosus
More informationLOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
Locally Available Biologic Agents in the Treatment of Psoriatic Arthritis 253 Phil. J. Internal Medicine, 47: 253-259, Nov.-Dec., 2009 LOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS
More informationReporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation
Reporting Autoimmune Diseases in Hematopoietic Stem Cell Transplantation Marcelo C. Pasquini, MD, MSc HVD05_1.ppt Outline Review of autoimmune diseases (AID). Role of transplantation for AID Data collection:
More informationSkin Manifestations of Drug Reactions
Skin Manifestations of Drug Reactions Dr Carol Hlela, Division of Dermatology Department of Medicine, University of Cape Town and Red Cross Children s Hospital What are the Skin Manifestations of Drug
More information2019 update on pyoderma gangrenosum
2019 update on pyoderma gangrenosum Kanade Shinkai, MD PhD University of California, San Francisco F106: Updates in neutrophilic and pustular dermatoses I have no conflicts of interest to disclose. I will
More informationTools to Aid in the Accurate Diagnosis of. Connective Tissue Disease
Connective Tissue Disease Tools to Aid in the Accurate Diagnosis of Connective Tissue Disease Connective Tissue Disease High quality assays and novel tests Inova offers a complete array of assay methods,
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationContents. Welcome to EULAR 2012 Berlin... iii AbstractsReviewers... iv. Speakers Abstracts
vii Welcome to EULAR 2012 Berlin... iii AbstractsReviewers... iv Speaker Presentations Speakers Abstracts Wednesday, 6 June 2012 SP0001 Pre-conference outlook... 2 SP0002 WIN Session 1... 2 SP0003 SP0005
More informationUvA-DARE (Digital Academic Repository) Innovative therapies and new targets in psoriasis de Groot, M. Link to publication
UvA-DARE (Digital Academic Repository) Innovative therapies and new targets in psoriasis de Groot, M. Link to publication Citation for published version (APA): de Groot, M. (2011). Innovative therapies
More informationESCMID Online Lecture Library. by author
Therapies or diseases predisposing to infection Congenital immunodeficiences Acquired conditions Common variable immunedeficiency particular diseases (e.g. HIV, cancer,leukemia, lymphoma, diabetes, cystic
More informationRheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations. Heather Hansen, MD
Rheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations Heather Hansen, MD Objectives Know Broad Categories of Rheumatoid Arthritis Medications
More information9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 1 Other Types of Lupus Discoid Lupus Erythematosus Lupus Pernio --- Sarcoidosis Lupus Vulgaris --- Tuberculosis of the face Manifestations of SLE Fever Rashes Arthritis
More informationIs it Autoimmune or NOT! Presented to AONP! October 2015!
Is it Autoimmune or NOT! Presented to AONP! October 2015! Four main jobs of immune system Detects Contains and eliminates Self regulates Protects Innate Immune System! Epithelial cells, phagocytic cells
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationNATIONAL LABORATORY HANDBOOK. Laboratory Testing for Antinuclear antibodies
NATIONAL LABORATORY HANDBOOK Laboratory Testing for Antinuclear antibodies Document reference number CSPD013/2018 Document developed by National Clinical Programme for Pathology Revision number Version
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationTransla&onal Opportuni&es
Suppor&ng the UK s Transla&onal Research in Paediatric Rheumatology Experience of the UK s Paediatric Rheumatology Clinical Studies Group West Midlands Annual Mee.ng Birmingham, 4 th July 03 Professor
More information9/13/2015. Nothing to disclose
Jared Bozeman Kathleen Luskin MD Bipin Thapa MD Medical College of Wisconsin Milwaukee, Wisconsin Nothing to disclose 24 Year old previously healthy woman presenting from OSH Fatigue Weakness Neck swelling
More informationDisclosures. Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies. None
Rheumatological Approaches to Differential Diagnosis, Physical Examination, and Interpretation of Studies Sarah Goglin MD Assistant Professor of Medicine Division of Rheumatology Disclosures None 1 [footer
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationCoccidioidomycosis in Rheumatologic Patients. Susan E. Hoover, MD
Coccidioidomycosis in Rheumatologic Patients Susan E. Hoover, MD The problem Prevalence of rheumatoid arthritis is 1% Population of Arizona is 6 million At least 150,000 new cocci infections yearly DMARDs
More informationAn otherwise healthy 12-year-old
1105 Photo Rounds.finalREV 10/19/05 2:05 PM Page 947 A young girl with scaly skin plaques The patient had numerous thick red plaques on her back and the extensor surfaces of elbows, knees, and forearms
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: belimumab_benlysta 6/2011 2/2018 2/2019 3/2018 Description of Procedure or Service Belimumab (Benlysta) is
More informationPID and autoimmunity, treatment options
PID and autoimmunity, treatment options Alain Fischer Hôpital Necker Enfants Malades, Inserm, Université Paris-Descartes, Institut Imagine, Collège de France, Paris PID, monogenic diseases and autoimmunity
More informationCutanous Manifestation of Lupus Erythematosus. Presented By: Dr. Naif S. Al Shahrani Salman Bin Abdaziz university
Cutanous Manifestation of Lupus Erythematosus Presented By: Dr. Naif S. Al Shahrani Salman Bin Abdaziz university A 50-year old lady, who is otherwise healthy, presented to the dermatology clinic with
More informationTolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases. Abul K. Abbas UCSF
Tolerance, autoimmunity and the pathogenesis of immunemediated inflammatory diseases Abul K. Abbas UCSF Balancing lymphocyte activation and control Activation Effector T cells Tolerance Regulatory T cells
More informationEmergent and Urgent Dermatology, Eruptions, and Wound Care
Emergent and Urgent Dermatology, Eruptions, and Wound Care G. Scott Drew, DO, FAAD, FAOCD Smith Clinic Department of Dermatology Tucson Osteopathic Medical Foundation April 27, 2018 Acute Cutaneous Lupus
More informationThe Power of the ANA. April 2018 Emily Littlejohn, DO MPH
Emergent Rheumatologic Diseases and Disorders for Primary Care. The Power of the ANA April 2018 Emily Littlejohn, DO MPH Question 1: the ANA test is: A) A screening test with high specificity to diagnose
More informationJuvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis (JIA) Kaveh Ardalan, MD, MS Division of Rheumatology Ann & Robert H. Lurie Children s Hospital of Chicago Assistant Professor, Pediatrics and Medical Social Sciences Northwestern
More informationPHM142 Autoimmune Disorders + Idiosyncratic Drug Reactions
PHM142 Autoimmune Disorders + Idiosyncratic Drug Reactions 1 Autoimmune Disorders Auto-reactivity: low physiological levels (e.g. tolerance) vs. pathogenic levels 80+ types of autoimmune diseases affect
More informationUse of extrapolation in small clinical trials:
Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis Jessica J. Lee, MD, MMSc Medical Officer Division of Gastroenterology and Inborn Errors Products CDER/ FDA 1 Learning
More informationInfections and Biologics
Overview Infections and Biologics James Galloway What is the risk of infection with biologics? Are some patients at greater risk? Are some drugs safer? Case scenario You recently commenced Judith, a 54
More information1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.
Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically
More informationDiseases of Immunity 2017 CL Davis General Pathology. Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc.
Diseases of Immunity 2017 CL Davis General Pathology Paul W. Snyder, DVM, PhD Experimental Pathology Laboratories, Inc. Autoimmunity Reflects a loss of immunologic tolerance Mechanisms Auto-antibodies
More informationThe relationship between PML-rituximab and other immunobiologicals: an overview
The relationship between PML-rituximab and other immunobiologicals: an overview Renaud Du Pasquier, M.D. Associate professor in Neurology Neuroimmunology University Hospital of Vaud, Switzerland Transatlantic
More informationPsoriasis. Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center
Psoriasis Jessica Kaffenberger, M.D. Assistant Professor of Dermatology Division of Dermatology The Ohio State University Wexner Medical Center Learning objectives Recognize the different types of psoriasis
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationBudsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital
Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases Outline What is ANA? How to detect ANA? Clinical
More information